

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																							
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																																						
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	OS																																																																																																						
研究デザイン		III b	文献数	2																																																																																																					
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																																							
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																						
効果指標	Hazard Ratio	統合値	1.03 (0.91 - 1.15) P=0.68																																																																																																						
効果指標	Risk Difference	統合値	0.01 (-0.14 , 0.06) P=0.68																																																																																																						
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Hazard Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>273</td> <td>588</td> <td>351</td> <td>775</td> <td>100.0%</td> <td>1.03 [0.91, 1.15]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>588</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>1.03 [0.91, 1.15]</b></td> <td></td> </tr> <tr> <td>Total events</td> <td>273</td> <td></td> <td>351</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable Test for overall effect: Z = 0.42 (P = 0.68)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Fixed, 95% CI</th> <th>M-H, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>273</td> <td>588</td> <td>351</td> <td>775</td> <td>100.0%</td> <td>0.01 [-0.04, 0.06]</td> <td></td> </tr> <tr> <td>PERUSE</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>Not estimable</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>588</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>0.01 [-0.04, 0.06]</b></td> <td></td> </tr> <tr> <td>Total events</td> <td>273</td> <td></td> <td>351</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable Test for overall effect: Z = 0.42 (P = 0.68)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Hazard Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	273	588	351	775	100.0%	1.03 [0.91, 1.15]		<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>1.03 [0.91, 1.15]</b>		Total events	273		351					Heterogeneity: Not applicable Test for overall effect: Z = 0.42 (P = 0.68)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	PERUSE	273	588	351	775	100.0%	0.01 [-0.04, 0.06]		PERUSE	0	0	0	0		Not estimable		<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>0.01 [-0.04, 0.06]</b>		Total events	273		351					Heterogeneity: Not applicable Test for overall effect: Z = 0.42 (P = 0.68)							
Study or Subgroup	Experimental		Control		Weight		Hazard Ratio																																																																																																		
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																		
PERUSE	273	588	351	775	100.0%	1.03 [0.91, 1.15]																																																																																																			
<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>1.03 [0.91, 1.15]</b>																																																																																																			
Total events	273		351																																																																																																						
Heterogeneity: Not applicable Test for overall effect: Z = 0.42 (P = 0.68)																																																																																																									
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																																			
	Events	Total	Events	Total		M-H, Fixed, 95% CI	M-H, Fixed, 95% CI																																																																																																		
PERUSE	273	588	351	775	100.0%	0.01 [-0.04, 0.06]																																																																																																			
PERUSE	0	0	0	0		Not estimable																																																																																																			
<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>0.01 [-0.04, 0.06]</b>																																																																																																			
Total events	273		351																																																																																																						
Heterogeneity: Not applicable Test for overall effect: Z = 0.42 (P = 0.68)																																																																																																									
ファンネル プロット	コメント：																																																																																																								
その他の解析																																																																																																									
メタリグ レッション																																																																																																									
感度分析																																																																																																									

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																														
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	PFS																																																																																														
研究デザイン		III b	文献数	2																																																																																													
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																														
効果指標	Hazard Ratio	統合値	0.98 (0.90 - 1.07) P=0.64																																																																																														
効果指標	Risk Difference	統合値	(-0.06 , 0.04) P=0.64																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Hazard Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>356</td> <td>588</td> <td>479</td> <td>775</td> <td>100.0%</td> <td>0.98</td> <td>[0.90, 1.07]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>588</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>0.98</b></td> <td><b>[0.90, 1.07]</b></td> </tr> <tr> <td>Total events</td> <td>356</td> <td></td> <td>479</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable Test for overall effect: Z = 0.47 (P = 0.64)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>356</td> <td>588</td> <td>479</td> <td>775</td> <td>100.0%</td> <td>-0.01</td> <td>[-0.06, 0.04]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>588</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>-0.01</b></td> <td><b>[-0.06, 0.04]</b></td> </tr> <tr> <td>Total events</td> <td>356</td> <td></td> <td>479</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable Test for overall effect: Z = 0.47 (P = 0.64)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Hazard Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	356	588	479	775	100.0%	0.98	[0.90, 1.07]	<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>0.98</b>	<b>[0.90, 1.07]</b>	Total events	356		479					Heterogeneity: Not applicable Test for overall effect: Z = 0.47 (P = 0.64)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	356	588	479	775	100.0%	-0.01	[-0.06, 0.04]	<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>-0.01</b>	<b>[-0.06, 0.04]</b>	Total events	356		479					Heterogeneity: Not applicable Test for overall effect: Z = 0.47 (P = 0.64)							
Study or Subgroup	Experimental		Control		Weight		Hazard Ratio																																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																										
PERUSE	356	588	479	775	100.0%	0.98	[0.90, 1.07]																																																																																										
<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>0.98</b>	<b>[0.90, 1.07]</b>																																																																																										
Total events	356		479																																																																																														
Heterogeneity: Not applicable Test for overall effect: Z = 0.47 (P = 0.64)																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																										
PERUSE	356	588	479	775	100.0%	-0.01	[-0.06, 0.04]																																																																																										
<b>Total (95% CI)</b>		<b>588</b>		<b>775</b>	<b>100.0%</b>	<b>-0.01</b>	<b>[-0.06, 0.04]</b>																																																																																										
Total events	356		479																																																																																														
Heterogeneity: Not applicable Test for overall effect: Z = 0.47 (P = 0.64)																																																																																																	
ファンネル プロット	コメント：																																																																																																
その他の解析					コメント																																																																																												
メタリグ レッション																																																																																																	
感度分析																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																																														
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	治療関連有害事象（末梢神経障害 all grades）																																																																																																														
研究デザイン		III b	文献数	2																																																																																																													
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																														
効果指標	Risk Ratio	統合値	2.6 (1.78 - 3.78) P<0.00001																																																																																																														
効果指標	Risk Difference	統合値	0.08 (0.05 - 0.11) P<0.00001																																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>75</td> <td>589</td> <td>38</td> <td>775</td> <td>100.0%</td> <td>2.60 [1.78, 3.78]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>2.60 [1.78, 3.78]</b></td> <td></td> </tr> <tr> <td colspan="8">Total events: 75 (Experimental), 38 (Control)</td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 4.98 (P &lt; 0.00001)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>75</td> <td>589</td> <td>38</td> <td>775</td> <td>100.0%</td> <td>0.08 [0.05, 0.11]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>0.08 [0.05, 0.11]</b></td> <td></td> </tr> <tr> <td colspan="8">Total events: 75 (Experimental), 38 (Control)</td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 4.96 (P &lt; 0.00001)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	75	589	38	775	100.0%	2.60 [1.78, 3.78]		<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>2.60 [1.78, 3.78]</b>		Total events: 75 (Experimental), 38 (Control)								Heterogeneity: Not applicable								Test for overall effect: Z = 4.98 (P < 0.00001)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	75	589	38	775	100.0%	0.08 [0.05, 0.11]		<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.08 [0.05, 0.11]</b>		Total events: 75 (Experimental), 38 (Control)								Heterogeneity: Not applicable								Test for overall effect: Z = 4.96 (P < 0.00001)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																										
PERUSE	75	589	38	775	100.0%	2.60 [1.78, 3.78]																																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>2.60 [1.78, 3.78]</b>																																																																																																											
Total events: 75 (Experimental), 38 (Control)																																																																																																																	
Heterogeneity: Not applicable																																																																																																																	
Test for overall effect: Z = 4.98 (P < 0.00001)																																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																										
PERUSE	75	589	38	775	100.0%	0.08 [0.05, 0.11]																																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.08 [0.05, 0.11]</b>																																																																																																											
Total events: 75 (Experimental), 38 (Control)																																																																																																																	
Heterogeneity: Not applicable																																																																																																																	
Test for overall effect: Z = 4.96 (P < 0.00001)																																																																																																																	
ファンネル プロット	コメント：明らかな出版バイアスは認めなかった。																																																																																																																
その他の解析																																																																																																																	
メタリグ レッション																																																																																																																	
感度分析																																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																																														
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	治療関連有害事象(下痢 all grades)																																																																																																														
研究デザイン		III b	文献数	2																																																																																																													
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																														
効果指標	Risk Ratio	統合値	0.98 (0.91 - 1.05) P=0.55																																																																																																														
効果指標	Risk Difference	統合値	-0.02 (-0.06 , 0.03)																																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio IV, Random, 95% CI</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>IV, Random, 95% CI</th> <th>IV, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>400</td> <td>589</td> <td>538</td> <td>775</td> <td>100.0%</td> <td>0.98 [0.91, 1.05]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>0.98 [0.91, 1.05]</b></td> <td></td> </tr> <tr> <td colspan="8">Total events: 400 (Experimental), 538 (Control)</td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 0.59 (P = 0.55)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference IV, Random, 95% CI</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>IV, Random, 95% CI</th> <th>IV, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>400</td> <td>589</td> <td>538</td> <td>775</td> <td>100.0%</td> <td>-0.02 [-0.06, 0.03]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>-0.02 [-0.06, 0.03]</b></td> <td></td> </tr> <tr> <td colspan="8">Total events: 400 (Experimental), 538 (Control)</td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 0.59 (P = 0.55)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio IV, Random, 95% CI		Events	Total	Events	Total	IV, Random, 95% CI	IV, Random, 95% CI	PERUSE	400	589	538	775	100.0%	0.98 [0.91, 1.05]		<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.98 [0.91, 1.05]</b>		Total events: 400 (Experimental), 538 (Control)								Heterogeneity: Not applicable								Test for overall effect: Z = 0.59 (P = 0.55)								Study or Subgroup	Experimental		Control		Weight	Risk Difference IV, Random, 95% CI		Events	Total	Events	Total	IV, Random, 95% CI	IV, Random, 95% CI	PERUSE	400	589	538	775	100.0%	-0.02 [-0.06, 0.03]		<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>-0.02 [-0.06, 0.03]</b>		Total events: 400 (Experimental), 538 (Control)								Heterogeneity: Not applicable								Test for overall effect: Z = 0.59 (P = 0.55)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio IV, Random, 95% CI																																																																																																										
	Events	Total	Events	Total		IV, Random, 95% CI	IV, Random, 95% CI																																																																																																										
PERUSE	400	589	538	775	100.0%	0.98 [0.91, 1.05]																																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.98 [0.91, 1.05]</b>																																																																																																											
Total events: 400 (Experimental), 538 (Control)																																																																																																																	
Heterogeneity: Not applicable																																																																																																																	
Test for overall effect: Z = 0.59 (P = 0.55)																																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference IV, Random, 95% CI																																																																																																											
	Events	Total	Events	Total		IV, Random, 95% CI	IV, Random, 95% CI																																																																																																										
PERUSE	400	589	538	775	100.0%	-0.02 [-0.06, 0.03]																																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>-0.02 [-0.06, 0.03]</b>																																																																																																											
Total events: 400 (Experimental), 538 (Control)																																																																																																																	
Heterogeneity: Not applicable																																																																																																																	
Test for overall effect: Z = 0.59 (P = 0.55)																																																																																																																	
ファンネル プロット	コメント：明らかな出版バイアスは認めなかった。																																																																																																																
その他の解析					コメント：																																																																																																												
メタリグ レッション																																																																																																																	
感度分析																																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																																														
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	治療関連有害事象(好中球減少症 all grades)																																																																																																														
研究デザイン		III b	文献数	2																																																																																																													
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																														
効果指標	Risk Ratio	統合値	0.72 (0.57 - 0.91) P=0.007																																																																																																														
効果指標	Risk Difference	統合値	-0.06 (-0.10, -0.02) P=0.005																																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>87</td> <td>589</td> <td>155</td> <td>755</td> <td>100.0%</td> <td>0.72 [0.57, 0.91]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>755</b></td> <td><b>100.0%</b></td> <td><b>0.72 [0.57, 0.91]</b></td> <td></td> </tr> <tr> <td>Total events</td> <td>87</td> <td></td> <td>155</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 2.69 (P = 0.007)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>87</td> <td>589</td> <td>155</td> <td>755</td> <td>100.0%</td> <td>-0.06 [-0.10, -0.02]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>755</b></td> <td><b>100.0%</b></td> <td><b>-0.06 [-0.10, -0.02]</b></td> <td></td> </tr> <tr> <td>Total events</td> <td>87</td> <td></td> <td>155</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 2.78 (P = 0.005)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	87	589	155	755	100.0%	0.72 [0.57, 0.91]		<b>Total (95% CI)</b>		<b>589</b>		<b>755</b>	<b>100.0%</b>	<b>0.72 [0.57, 0.91]</b>		Total events	87		155					Heterogeneity: Not applicable								Test for overall effect: Z = 2.69 (P = 0.007)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	87	589	155	755	100.0%	-0.06 [-0.10, -0.02]		<b>Total (95% CI)</b>		<b>589</b>		<b>755</b>	<b>100.0%</b>	<b>-0.06 [-0.10, -0.02]</b>		Total events	87		155					Heterogeneity: Not applicable								Test for overall effect: Z = 2.78 (P = 0.005)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																										
PERUSE	87	589	155	755	100.0%	0.72 [0.57, 0.91]																																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>755</b>	<b>100.0%</b>	<b>0.72 [0.57, 0.91]</b>																																																																																																											
Total events	87		155																																																																																																														
Heterogeneity: Not applicable																																																																																																																	
Test for overall effect: Z = 2.69 (P = 0.007)																																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																										
PERUSE	87	589	155	755	100.0%	-0.06 [-0.10, -0.02]																																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>755</b>	<b>100.0%</b>	<b>-0.06 [-0.10, -0.02]</b>																																																																																																											
Total events	87		155																																																																																																														
Heterogeneity: Not applicable																																																																																																																	
Test for overall effect: Z = 2.78 (P = 0.005)																																																																																																																	
ファンネル プロット	コメント：明らかな出版バイアスは認めなかった。																																																																																																																
その他の解析																																																																																																																	
メタリグ レッション																																																																																																																	
感度分析																																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																																																							
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																																																																						
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	治療関連有害事象（発熱性好中球減少症）																																																																																																																																						
研究デザイン		III b	文献数	2																																																																																																																																					
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																																																																							
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																																																						
効果指標	Risk Ratio	統合値	0.11 (0.05 - 0.24) P<0.00001																																																																																																																																						
効果指標	Risk Difference	統合値	-0.09 (-0.12 , -0.07) P<0.00001																																																																																																																																						
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>7</td> <td>589</td> <td>82</td> <td>775</td> <td>100.0%</td> <td>0.11 [0.05, 0.24]</td> <td colspan="3"></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>0.11 [0.05, 0.24]</b></td> <td colspan="3"></td> </tr> <tr> <td colspan="10">Total events: 7 (Experimental), 82 (Control)</td> </tr> <tr> <td colspan="10">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="10">Test for overall effect: Z = 5.61 (P &lt; 0.00001)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>7</td> <td>589</td> <td>82</td> <td>775</td> <td>100.0%</td> <td>-0.09 [-0.12, -0.07]</td> <td colspan="3"></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>-0.09 [-0.12, -0.07]</b></td> <td colspan="3"></td> </tr> <tr> <td colspan="10">Total events: 7 (Experimental), 82 (Control)</td> </tr> <tr> <td colspan="10">Heterogeneity: Not applicable</td> </tr> <tr> <td colspan="10">Test for overall effect: Z = 7.88 (P &lt; 0.00001)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	7	589	82	775	100.0%	0.11 [0.05, 0.24]				<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.11 [0.05, 0.24]</b>				Total events: 7 (Experimental), 82 (Control)										Heterogeneity: Not applicable										Test for overall effect: Z = 5.61 (P < 0.00001)										Study or Subgroup	Experimental		Control		Weight	Risk Difference		Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	7	589	82	775	100.0%	-0.09 [-0.12, -0.07]				<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>-0.09 [-0.12, -0.07]</b>				Total events: 7 (Experimental), 82 (Control)										Heterogeneity: Not applicable										Test for overall effect: Z = 7.88 (P < 0.00001)									
Study or Subgroup	Experimental		Control		Weight		Risk Ratio		Risk Ratio																																																																																																																																
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																																		
PERUSE	7	589	82	775	100.0%	0.11 [0.05, 0.24]																																																																																																																																			
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.11 [0.05, 0.24]</b>																																																																																																																																			
Total events: 7 (Experimental), 82 (Control)																																																																																																																																									
Heterogeneity: Not applicable																																																																																																																																									
Test for overall effect: Z = 5.61 (P < 0.00001)																																																																																																																																									
Study or Subgroup	Experimental		Control		Weight	Risk Difference		Risk Difference																																																																																																																																	
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																																		
PERUSE	7	589	82	775	100.0%	-0.09 [-0.12, -0.07]																																																																																																																																			
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>-0.09 [-0.12, -0.07]</b>																																																																																																																																			
Total events: 7 (Experimental), 82 (Control)																																																																																																																																									
Heterogeneity: Not applicable																																																																																																																																									
Test for overall effect: Z = 7.88 (P < 0.00001)																																																																																																																																									
ファンネル プロット	コメント：明らかな出版バイアスは認めなかった。																																																																																																																																								
その他の解析				コメント：																																																																																																																																					
メタリグ レッション																																																																																																																																									
感度分析																																																																																																																																									

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ、ペルツズマブ、パクリタキセル併用療法																																																																																														
C	トラスツズマブ、ペルツズマブ、ドセタキセル併用療法	O	治療関連有害事象 (EF低下：all grades)																																																																																														
研究デザイン		III b	文献数	2																																																																																													
コード		PERUSE trial ① <a href="https://doi.org/10.1016/j.annonc.2021.06.024">https://doi.org/10.1016/j.annonc.2021.06.024</a> 、 ② <a href="https://doi.org/10.1093/annonc/mdz061">https://doi.org/10.1093/annonc/mdz061</a>																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																														
効果指標	Risk Ratio	統合値	1.33 (0.99 - 1.81) P=0.06																																																																																														
効果指標	Risk Difference	統合値	0.03 (-0.00 - 0.07) P=0.07																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>75</td> <td>589</td> <td>74</td> <td>775</td> <td>100.0%</td> <td>1.33 [0.99, 1.81]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>1.33 [0.99, 1.81]</b></td> <td></td> </tr> <tr> <td>Total events</td> <td>75</td> <td></td> <td>74</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable Test for overall effect: Z = 1.86 (P = 0.06)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>PERUSE</td> <td>75</td> <td>589</td> <td>74</td> <td>775</td> <td>100.0%</td> <td>0.03 [-0.00, 0.07]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>589</b></td> <td></td> <td><b>775</b></td> <td><b>100.0%</b></td> <td><b>0.03 [-0.00, 0.07]</b></td> <td></td> </tr> <tr> <td>Total events</td> <td>75</td> <td></td> <td>74</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Not applicable Test for overall effect: Z = 1.84 (P = 0.07)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	75	589	74	775	100.0%	1.33 [0.99, 1.81]		<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>1.33 [0.99, 1.81]</b>		Total events	75		74					Heterogeneity: Not applicable Test for overall effect: Z = 1.86 (P = 0.06)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	PERUSE	75	589	74	775	100.0%	0.03 [-0.00, 0.07]		<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.03 [-0.00, 0.07]</b>		Total events	75		74					Heterogeneity: Not applicable Test for overall effect: Z = 1.84 (P = 0.07)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																										
PERUSE	75	589	74	775	100.0%	1.33 [0.99, 1.81]																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>1.33 [0.99, 1.81]</b>																																																																																											
Total events	75		74																																																																																														
Heterogeneity: Not applicable Test for overall effect: Z = 1.86 (P = 0.06)																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																										
PERUSE	75	589	74	775	100.0%	0.03 [-0.00, 0.07]																																																																																											
<b>Total (95% CI)</b>		<b>589</b>		<b>775</b>	<b>100.0%</b>	<b>0.03 [-0.00, 0.07]</b>																																																																																											
Total events	75		74																																																																																														
Heterogeneity: Not applicable Test for overall effect: Z = 1.84 (P = 0.07)																																																																																																	
ファンネル プロット	コメント：明らかな出版バイアスは認めなかった。																																																																																																
その他の解析				コメント：																																																																																													
メタリグ レッション																																																																																																	
感度分析																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																					
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法																																																																																																				
C	トラスツズマブ+タキサン併用療法	O	OS																																																																																																				
研究デザイン		RCT	文献数	2																																																																																																			
コード		CLEOPATRA PUFFIN																																																																																																					
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																				
効果指標	Hazard Ratio	統合値	0.6 (0.46 - 0.78) P=0.0002																																																																																																				
効果指標	Risk Difference	統合値	-0.12 (-0.18 - 0.07) P<0.00001																																																																																																				
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Experimental Events</th> <th>Experimental Total</th> <th>Control Events</th> <th>Control Total</th> <th>Weight</th> <th>Hazard Ratio IV, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>235</td> <td>402</td> <td>280</td> <td>406</td> <td>86.8%</td> <td>0.63 [0.47, 0.85]</td> </tr> <tr> <td>PUFFIN</td> <td>12</td> <td>122</td> <td>25</td> <td>120</td> <td>13.2%</td> <td>0.41 [0.20, 0.87]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>524</b></td> <td></td> <td><b>526</b></td> <td><b>100.0%</b></td> <td><b>0.60 [0.46, 0.78]</b></td> </tr> <tr> <td colspan="7">Total events: 247 305</td> </tr> <tr> <td colspan="7">Heterogeneity: Chi<sup>2</sup> = 1.09, df = 1 (P = 0.30); I<sup>2</sup> = 8%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 3.73 (P = 0.0002)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Experimental Events</th> <th>Experimental Total</th> <th>Control Events</th> <th>Control Total</th> <th>Weight</th> <th>Risk Difference M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>235</td> <td>420</td> <td>280</td> <td>406</td> <td>65.4%</td> <td>-0.13 [-0.20, -0.06]</td> </tr> <tr> <td>PUFFIN</td> <td>12</td> <td>122</td> <td>25</td> <td>120</td> <td>34.6%</td> <td>-0.11 [-0.20, -0.02]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>542</b></td> <td></td> <td><b>526</b></td> <td><b>100.0%</b></td> <td><b>-0.12 [-0.18, -0.07]</b></td> </tr> <tr> <td colspan="7">Total events: 247 305</td> </tr> <tr> <td colspan="7">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.13, df = 1 (P = 0.71); I<sup>2</sup> = 0%</td> </tr> <tr> <td colspan="7">Test for overall effect: Z = 4.56 (P &lt; 0.00001)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Hazard Ratio IV, Fixed, 95% CI	CLEOPATRA	235	402	280	406	86.8%	0.63 [0.47, 0.85]	PUFFIN	12	122	25	120	13.2%	0.41 [0.20, 0.87]	<b>Total (95% CI)</b>		<b>524</b>		<b>526</b>	<b>100.0%</b>	<b>0.60 [0.46, 0.78]</b>	Total events: 247 305							Heterogeneity: Chi <sup>2</sup> = 1.09, df = 1 (P = 0.30); I <sup>2</sup> = 8%							Test for overall effect: Z = 3.73 (P = 0.0002)							Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Difference M-H, Random, 95% CI	CLEOPATRA	235	420	280	406	65.4%	-0.13 [-0.20, -0.06]	PUFFIN	12	122	25	120	34.6%	-0.11 [-0.20, -0.02]	<b>Total (95% CI)</b>		<b>542</b>		<b>526</b>	<b>100.0%</b>	<b>-0.12 [-0.18, -0.07]</b>	Total events: 247 305							Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.13, df = 1 (P = 0.71); I <sup>2</sup> = 0%							Test for overall effect: Z = 4.56 (P < 0.00001)						
Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Hazard Ratio IV, Fixed, 95% CI																																																																																																	
CLEOPATRA	235	402	280	406	86.8%	0.63 [0.47, 0.85]																																																																																																	
PUFFIN	12	122	25	120	13.2%	0.41 [0.20, 0.87]																																																																																																	
<b>Total (95% CI)</b>		<b>524</b>		<b>526</b>	<b>100.0%</b>	<b>0.60 [0.46, 0.78]</b>																																																																																																	
Total events: 247 305																																																																																																							
Heterogeneity: Chi <sup>2</sup> = 1.09, df = 1 (P = 0.30); I <sup>2</sup> = 8%																																																																																																							
Test for overall effect: Z = 3.73 (P = 0.0002)																																																																																																							
Study or Subgroup	Experimental Events	Experimental Total	Control Events	Control Total	Weight	Risk Difference M-H, Random, 95% CI																																																																																																	
CLEOPATRA	235	420	280	406	65.4%	-0.13 [-0.20, -0.06]																																																																																																	
PUFFIN	12	122	25	120	34.6%	-0.11 [-0.20, -0.02]																																																																																																	
<b>Total (95% CI)</b>		<b>542</b>		<b>526</b>	<b>100.0%</b>	<b>-0.12 [-0.18, -0.07]</b>																																																																																																	
Total events: 247 305																																																																																																							
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.13, df = 1 (P = 0.71); I <sup>2</sup> = 0%																																																																																																							
Test for overall effect: Z = 4.56 (P < 0.00001)																																																																																																							
ファンネル プロット																																																																																																							
コメント：																																																																																																							
その他の解析																																																																																																							
メタリグ レッション																																																																																																							
感度分析																																																																																																							



【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																			
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法																																																																		
C	トラスツズマブ+タキサン併用療法	O	PFS																																																																		
研究デザイン	RCT	文献数	2																																																																		
コード	CLEOPATRA PUFFIN																																																																				
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																		
効果指標	Hazard Ratio	統合値	0.69 (0.60 - 0.80) P<0.00001																																																																		
効果指標	Risk Difference	統合値	-0.12 (-0.18 - 0.07) P<0.00001																																																																		
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th rowspan="2">log[Hazard Ratio]</th> <th rowspan="2">SE</th> <th rowspan="2">Weight</th> <th colspan="2">Hazard Ratio</th> </tr> <tr> <th>IV, Fixed, 95% CI</th> <th>IV, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>-0.3711</td> <td>0.0799</td> <td>82.7%</td> <td>0.69 [0.59, 0.81]</td> <td></td> </tr> <tr> <td>PUFFIN</td> <td>-0.3711</td> <td>0.1746</td> <td>17.3%</td> <td>0.69 [0.49, 0.97]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td></td> <td><b>100.0%</b></td> <td><b>0.69 [0.60, 0.80]</b></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Chi<sup>2</sup> = 0.00, df = 1 (P = 1.00); I<sup>2</sup> = 0% Test for overall effect: Z = 5.11 (P &lt; 0.00001)</p> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>284</td> <td>402</td> <td>320</td> <td>406</td> <td>81.4%</td> <td>-0.08 [-0.14, -0.02]</td> <td></td> </tr> <tr> <td>PUFFIN</td> <td>57</td> <td>122</td> <td>71</td> <td>120</td> <td>18.6%</td> <td>-0.12 [-0.25, 0.00]</td> <td></td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>524</b></td> <td></td> <td><b>526</b></td> <td><b>100.0%</b></td> <td><b>-0.09 [-0.14, -0.04]</b></td> <td></td> </tr> </tbody> </table> <p>Total events: 341 (Experimental), 391 (Control) Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.37, df = 1 (P = 0.54); I<sup>2</sup> = 0% Test for overall effect: Z = 3.26 (P = 0.001)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio		IV, Fixed, 95% CI	IV, Fixed, 95% CI	CLEOPATRA	-0.3711	0.0799	82.7%	0.69 [0.59, 0.81]		PUFFIN	-0.3711	0.1746	17.3%	0.69 [0.49, 0.97]		<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.69 [0.60, 0.80]</b>		Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	284	402	320	406	81.4%	-0.08 [-0.14, -0.02]		PUFFIN	57	122	71	120	18.6%	-0.12 [-0.25, 0.00]		<b>Total (95% CI)</b>		<b>524</b>		<b>526</b>	<b>100.0%</b>	<b>-0.09 [-0.14, -0.04]</b>	
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio																																																																	
				IV, Fixed, 95% CI	IV, Fixed, 95% CI																																																																
CLEOPATRA	-0.3711	0.0799	82.7%	0.69 [0.59, 0.81]																																																																	
PUFFIN	-0.3711	0.1746	17.3%	0.69 [0.49, 0.97]																																																																	
<b>Total (95% CI)</b>			<b>100.0%</b>	<b>0.69 [0.60, 0.80]</b>																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																															
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																														
CLEOPATRA	284	402	320	406	81.4%	-0.08 [-0.14, -0.02]																																																															
PUFFIN	57	122	71	120	18.6%	-0.12 [-0.25, 0.00]																																																															
<b>Total (95% CI)</b>		<b>524</b>		<b>526</b>	<b>100.0%</b>	<b>-0.09 [-0.14, -0.04]</b>																																																															
ファンネル プロット																																																																					
コメント：																																																																					
その他の解析					コメント																																																																
メタリグ レッション																																																																					
感度分析																																																																					

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法																																																																																																																														
C	トラスツズマブ+タキサン併用療法	O	治療関連有害事象 下痢G3以上																																																																																																																														
研究デザイン		RCT	文献数	2																																																																																																																													
コード		CLEOPATRA PUFFIN																																																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																																														
効果指標	Hazard Ratio	統合値	3.26 (0.43 - 25.0) P=0.25																																																																																																																														
効果指標	Risk Difference	統合値	0.02 (-0.00 - 0.04) P=0.01																																																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>7</td> <td>303</td> <td>0</td> <td>260</td> <td>33.4%</td> <td>12.88</td> <td>[0.74, 224.41]</td> </tr> <tr> <td>PUFFIN</td> <td>5</td> <td>122</td> <td>3</td> <td>120</td> <td>66.6%</td> <td>1.64</td> <td>[0.40, 6.71]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>425</b></td> <td></td> <td><b>380</b></td> <td><b>100.0%</b></td> <td><b>3.26</b></td> <td><b>[0.43, 25.00]</b></td> </tr> <tr> <td colspan="2">Total events</td> <td>12</td> <td colspan="2">3</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau<sup>2</sup> = 1.10; Chi<sup>2</sup> = 1.84, df = 1 (P = 0.18); I<sup>2</sup> = 46%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 1.14 (P = 0.25)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>7</td> <td>303</td> <td>0</td> <td>260</td> <td>85.9%</td> <td>0.02</td> <td>[0.00, 0.04]</td> </tr> <tr> <td>PUFFIN</td> <td>5</td> <td>122</td> <td>3</td> <td>120</td> <td>14.1%</td> <td>0.02</td> <td>[-0.03, 0.06]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>425</b></td> <td></td> <td><b>380</b></td> <td><b>100.0%</b></td> <td><b>0.02</b></td> <td><b>[0.01, 0.04]</b></td> </tr> <tr> <td colspan="2">Total events</td> <td>12</td> <td colspan="2">3</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.10, df = 1 (P = 0.75); I<sup>2</sup> = 0%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 2.56 (P = 0.01)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	7	303	0	260	33.4%	12.88	[0.74, 224.41]	PUFFIN	5	122	3	120	66.6%	1.64	[0.40, 6.71]	<b>Total (95% CI)</b>		<b>425</b>		<b>380</b>	<b>100.0%</b>	<b>3.26</b>	<b>[0.43, 25.00]</b>	Total events		12	3					Heterogeneity: Tau <sup>2</sup> = 1.10; Chi <sup>2</sup> = 1.84, df = 1 (P = 0.18); I <sup>2</sup> = 46%								Test for overall effect: Z = 1.14 (P = 0.25)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	7	303	0	260	85.9%	0.02	[0.00, 0.04]	PUFFIN	5	122	3	120	14.1%	0.02	[-0.03, 0.06]	<b>Total (95% CI)</b>		<b>425</b>		<b>380</b>	<b>100.0%</b>	<b>0.02</b>	<b>[0.01, 0.04]</b>	Total events		12	3					Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.10, df = 1 (P = 0.75); I <sup>2</sup> = 0%								Test for overall effect: Z = 2.56 (P = 0.01)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																										
CLEOPATRA	7	303	0	260	33.4%	12.88	[0.74, 224.41]																																																																																																																										
PUFFIN	5	122	3	120	66.6%	1.64	[0.40, 6.71]																																																																																																																										
<b>Total (95% CI)</b>		<b>425</b>		<b>380</b>	<b>100.0%</b>	<b>3.26</b>	<b>[0.43, 25.00]</b>																																																																																																																										
Total events		12	3																																																																																																																														
Heterogeneity: Tau <sup>2</sup> = 1.10; Chi <sup>2</sup> = 1.84, df = 1 (P = 0.18); I <sup>2</sup> = 46%																																																																																																																																	
Test for overall effect: Z = 1.14 (P = 0.25)																																																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																										
CLEOPATRA	7	303	0	260	85.9%	0.02	[0.00, 0.04]																																																																																																																										
PUFFIN	5	122	3	120	14.1%	0.02	[-0.03, 0.06]																																																																																																																										
<b>Total (95% CI)</b>		<b>425</b>		<b>380</b>	<b>100.0%</b>	<b>0.02</b>	<b>[0.01, 0.04]</b>																																																																																																																										
Total events		12	3																																																																																																																														
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.10, df = 1 (P = 0.75); I <sup>2</sup> = 0%																																																																																																																																	
Test for overall effect: Z = 2.56 (P = 0.01)																																																																																																																																	
ファンネル プロット	<p>コメント：明らかな出版バイアスは認めなかった。</p>																																																																																																																																
その他の解析					コメント：2 報告の解析。																																																																																																																												
メタリグ レッション																																																																																																																																	
感度分析																																																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法																																																																														
C	トラスツズマブ+タキサン併用療法	O	治療関連有害事象 好中球減少G3以上																																																																														
研究デザイン		RCT	文献数	2																																																																													
コード		CLEOPATRA PUFFIN																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																														
効果指標	Hazard Ratio	統合値	1.02 (0.91 - 1.16) P=0.71																																																																														
効果指標	Risk Difference	統合値	0.01 (-0.05 - 0.07) P=0.66																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>200</td> <td>408</td> <td>183</td> <td>396</td> <td>69.8%</td> <td>1.06</td> <td>[0.92, 1.23]</td> </tr> <tr> <td>PUFFIN</td> <td>67</td> <td>122</td> <td>70</td> <td>120</td> <td>30.2%</td> <td>0.94</td> <td>[0.75, 1.17]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>530</b></td> <td></td> <td><b>516</b></td> <td><b>100.0%</b></td> <td><b>1.02</b></td> <td><b>[0.91, 1.16]</b></td> </tr> </tbody> </table> <p>Total events: 267 (Experimental) / 253 (Control) Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.79, df = 1 (P = 0.37); I<sup>2</sup> = 0% Test for overall effect: Z = 0.37 (P = 0.71)</p> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>200</td> <td>408</td> <td>183</td> <td>396</td> <td>76.6%</td> <td>0.03</td> <td>[-0.04, 0.10]</td> </tr> <tr> <td>PUFFIN</td> <td>67</td> <td>122</td> <td>70</td> <td>120</td> <td>23.4%</td> <td>-0.03</td> <td>[-0.16, 0.09]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>530</b></td> <td></td> <td><b>516</b></td> <td><b>100.0%</b></td> <td><b>0.01</b></td> <td><b>[-0.05, 0.07]</b></td> </tr> </tbody> </table> <p>Total events: 267 (Experimental) / 253 (Control) Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.73, df = 1 (P = 0.39); I<sup>2</sup> = 0% Test for overall effect: Z = 0.44 (P = 0.66)</p>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	200	408	183	396	69.8%	1.06	[0.92, 1.23]	PUFFIN	67	122	70	120	30.2%	0.94	[0.75, 1.17]	<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>1.02</b>	<b>[0.91, 1.16]</b>	Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	200	408	183	396	76.6%	0.03	[-0.04, 0.10]	PUFFIN	67	122	70	120	23.4%	-0.03	[-0.16, 0.09]	<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>0.01</b>	<b>[-0.05, 0.07]</b>
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																										
CLEOPATRA	200	408	183	396	69.8%	1.06	[0.92, 1.23]																																																																										
PUFFIN	67	122	70	120	30.2%	0.94	[0.75, 1.17]																																																																										
<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>1.02</b>	<b>[0.91, 1.16]</b>																																																																										
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																										
CLEOPATRA	200	408	183	396	76.6%	0.03	[-0.04, 0.10]																																																																										
PUFFIN	67	122	70	120	23.4%	-0.03	[-0.16, 0.09]																																																																										
<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>0.01</b>	<b>[-0.05, 0.07]</b>																																																																										
ファンネル プロット	<p>コメント：明らかな出版バイアスは認めなかった。</p>																																																																																
その他の解析				コメント：2 報告の解析。																																																																													
メタリグ レッション																																																																																	
感度分析																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法																																																																																																																														
C	トラスツズマブ+タキサン併用療法	O	治療関連有害事象 発熱性好中球減少症																																																																																																																														
研究デザイン		RCT	文献数	2																																																																																																																													
コード		CLEOPATRA PUFFIN																																																																																																																															
モデル	ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																																																																														
効果指標	Hazard Ratio	統合値	1.80 (1.20 - 2.69) P=0.004																																																																																																																														
効果指標	Risk Difference	統合値	0.04 (-0.01 - 0.09) P=0.12																																																																																																																														
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>56</td> <td>408</td> <td>30</td> <td>396</td> <td>91.8%</td> <td>1.81</td> <td>[1.19, 2.76]</td> </tr> <tr> <td>PUFFIN</td> <td>5</td> <td>122</td> <td>3</td> <td>120</td> <td>8.2%</td> <td>1.64</td> <td>[0.40, 6.71]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>530</b></td> <td></td> <td><b>516</b></td> <td><b>100.0%</b></td> <td><b>1.80</b></td> <td><b>[1.20, 2.69]</b></td> </tr> <tr> <td colspan="2">Total events</td> <td>61</td> <td colspan="2">33</td> <td colspan="3"></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 0.02, df = 1 (P = 0.89); I<sup>2</sup> = 0%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 2.85 (P = 0.004)</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>56</td> <td>408</td> <td>30</td> <td>396</td> <td>51.1%</td> <td>0.06</td> <td>[0.02, 0.10]</td> </tr> <tr> <td>PUFFIN</td> <td>5</td> <td>122</td> <td>3</td> <td>120</td> <td>48.9%</td> <td>0.02</td> <td>[-0.03, 0.06]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>530</b></td> <td></td> <td><b>516</b></td> <td><b>100.0%</b></td> <td><b>0.04</b></td> <td><b>[-0.01, 0.09]</b></td> </tr> <tr> <td colspan="2">Total events</td> <td>61</td> <td colspan="2">33</td> <td colspan="3"></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau<sup>2</sup> = 0.00; Chi<sup>2</sup> = 2.57, df = 1 (P = 0.11); I<sup>2</sup> = 61%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 1.56 (P = 0.12)</td> </tr> </tbody> </table>					Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	56	408	30	396	91.8%	1.81	[1.19, 2.76]	PUFFIN	5	122	3	120	8.2%	1.64	[0.40, 6.71]	<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>1.80</b>	<b>[1.20, 2.69]</b>	Total events		61	33					Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.02, df = 1 (P = 0.89); I <sup>2</sup> = 0%								Test for overall effect: Z = 2.85 (P = 0.004)								Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	56	408	30	396	51.1%	0.06	[0.02, 0.10]	PUFFIN	5	122	3	120	48.9%	0.02	[-0.03, 0.06]	<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>0.04</b>	<b>[-0.01, 0.09]</b>	Total events		61	33					Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2.57, df = 1 (P = 0.11); I <sup>2</sup> = 61%								Test for overall effect: Z = 1.56 (P = 0.12)							
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																										
CLEOPATRA	56	408	30	396	91.8%	1.81	[1.19, 2.76]																																																																																																																										
PUFFIN	5	122	3	120	8.2%	1.64	[0.40, 6.71]																																																																																																																										
<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>1.80</b>	<b>[1.20, 2.69]</b>																																																																																																																										
Total events		61	33																																																																																																																														
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.02, df = 1 (P = 0.89); I <sup>2</sup> = 0%																																																																																																																																	
Test for overall effect: Z = 2.85 (P = 0.004)																																																																																																																																	
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																										
CLEOPATRA	56	408	30	396	51.1%	0.06	[0.02, 0.10]																																																																																																																										
PUFFIN	5	122	3	120	48.9%	0.02	[-0.03, 0.06]																																																																																																																										
<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>0.04</b>	<b>[-0.01, 0.09]</b>																																																																																																																										
Total events		61	33																																																																																																																														
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2.57, df = 1 (P = 0.11); I <sup>2</sup> = 61%																																																																																																																																	
Test for overall effect: Z = 1.56 (P = 0.12)																																																																																																																																	
ファンネル プロット	<p>コメント：明らかな出版バイアスは認めなかった。</p>																																																																																																																																
その他の解析					コメント：2 報告の解析。																																																																																																																												
メタリグ レッション																																																																																																																																	
感度分析																																																																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？																																																																															
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法																																																																														
C	トラスツズマブ+タキサン併用療法	O	治療関連有害事象 心毒性allgrade																																																																														
研究デザイン		RCT	文献数	2																																																																													
コード		CLEOPATRA PUFFIN																																																																															
モデル		ランダム効果	方法	Inverse variance (RevMan5.4.1)																																																																													
効果指標		Hazard Ratio	統合値	1.01 (0.18 - 5.55) P=0.99																																																																													
効果指標		Risk Difference	統合値	0.03 (-0.07 - 0.00) P=0.08																																																																													
フォレスト プロット		<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>22</td> <td>408</td> <td>34</td> <td>396</td> <td>77.0%</td> <td>0.63</td> <td>[0.37, 1.05]</td> </tr> <tr> <td>PUFFIN</td> <td>2</td> <td>122</td> <td>0</td> <td>120</td> <td>23.0%</td> <td>4.92</td> <td>[0.24, 101.39]</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>530</b></td> <td></td> <td><b>516</b></td> <td><b>100.0%</b></td> <td><b>1.01</b></td> <td><b>[0.18, 5.55]</b></td> </tr> </tbody> </table> <p>Total events: 24 (Experimental), 34 (Control) Heterogeneity: Tau<sup>2</sup> = 0.91; Chi<sup>2</sup> = 1.74, df = 1 (P = 0.19); I<sup>2</sup> = 43% Test for overall effect: Z = 0.01 (P = 0.99)</p> <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Experimental</th> <th colspan="2">Control</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Difference</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>CLEOPATRA</td> <td>22</td> <td>408</td> <td>34</td> <td>396</td> <td>100.0%</td> <td>-0.03</td> <td>[-0.07, 0.00]</td> </tr> <tr> <td>PUFFIN</td> <td>2</td> <td>122</td> <td>0</td> <td>120</td> <td></td> <td></td> <td>Not estimable</td> </tr> <tr> <td><b>Total (95% CI)</b></td> <td></td> <td><b>530</b></td> <td></td> <td><b>396</b></td> <td><b>100.0%</b></td> <td><b>-0.03</b></td> <td><b>[-0.07, 0.00]</b></td> </tr> </tbody> </table> <p>Total events: 24 (Experimental), 154 (Control) Heterogeneity: Not applicable Test for overall effect: Z = 1.78 (P = 0.08)</p>				Study or Subgroup	Experimental		Control		Weight	Risk Ratio		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	22	408	34	396	77.0%	0.63	[0.37, 1.05]	PUFFIN	2	122	0	120	23.0%	4.92	[0.24, 101.39]	<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>1.01</b>	<b>[0.18, 5.55]</b>	Study or Subgroup	Experimental		Control		Weight	Risk Difference		Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	CLEOPATRA	22	408	34	396	100.0%	-0.03	[-0.07, 0.00]	PUFFIN	2	122	0	120			Not estimable	<b>Total (95% CI)</b>		<b>530</b>		<b>396</b>	<b>100.0%</b>	<b>-0.03</b>	<b>[-0.07, 0.00]</b>
Study or Subgroup	Experimental		Control		Weight		Risk Ratio																																																																										
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																										
CLEOPATRA	22	408	34	396	77.0%	0.63	[0.37, 1.05]																																																																										
PUFFIN	2	122	0	120	23.0%	4.92	[0.24, 101.39]																																																																										
<b>Total (95% CI)</b>		<b>530</b>		<b>516</b>	<b>100.0%</b>	<b>1.01</b>	<b>[0.18, 5.55]</b>																																																																										
Study or Subgroup	Experimental		Control		Weight	Risk Difference																																																																											
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																										
CLEOPATRA	22	408	34	396	100.0%	-0.03	[-0.07, 0.00]																																																																										
PUFFIN	2	122	0	120			Not estimable																																																																										
<b>Total (95% CI)</b>		<b>530</b>		<b>396</b>	<b>100.0%</b>	<b>-0.03</b>	<b>[-0.07, 0.00]</b>																																																																										
ファンネル プロット		<p>コメント：明らかな出版バイアスは認めなかった。</p>																																																																															
その他の解析				コメント：2 報告の解析。																																																																													
メタリグ レッション																																																																																	
感度分析																																																																																	

【SR-10 メタアナリシス】

CQ		HER2陽性転移・再発乳癌に対する一次治療として、トラスツズマブ+ペルツズマブ+タキサン併用療法は推奨されるか？		
P	HER2陽性転移・再発乳癌に対する一次治療	I	トラスツズマブ+ペルツズマブ+タキサン併用療法	
C	トラスツズマブ+タキサン併用療法	O	HRQOL	
研究デザイン	RCT	文献数	1	
コード	CLEOPATRA			
モデル	ランダム効果	方法		
効果指標	Hazard Ratio	統合値		
効果指標	Risk Difference	統合値		
フォレスト プロット				
	コメント：			
ファンネル プロット				
	コメント：			
その他の解析				コメント：1報告の解析。
メタリグ レッション				
感度分析				